Table 5.
Multivariate analysis
| Relapse | NRM | Acute GVHD | Chronic GVHD | LFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| p value | HR (95 % CI) | p value | HR (95 % CI) | p value | OR (95 % CI) | p value | HR (95 % CI) | p value | HR (95 % CI) | p value | HR (95 % CI) | |
| HLA 10/10 (ref) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
| HLA 9/10 versus 10/10 | 0.038 | 1.18 (1.01–1.38) | 0.001 | 1.34 (1.13–1.58) | 0.0001 | 1.47 (1.21–1.79) | 0.418 | 1.07 (0.91–1.26) | 0.0001 | 1.25 (1.11–1.40) | 0.0001 | 1.27 (1.13–1.44) |
| HLA 8/10 versus 9/10 | 0.064 | 0.67 (0.43–1.02) | 0.398 | 1.17 (0.81–1.68) | 0.952 | 1.01 (0.63–1.62) | 0.145 | 1.31 (0.91–1.88) | 0.432 | 0.90 (0.68–1.18) | 0.557 | 0.92 (0.69–1.22) |
| Age at SCT (10 years) | 0.701 | 1.02 (0.91–1.15) | <10−5 | 1.41 (1.24–1.59) | 0.465 | 1.05 (0.91–1.22) | 0.501 | 1.04 (0.93–1.17) | 0.0001 | 1.18 (1.09–1.29) | <10−5 | 1.25 (1.14–1.37) |
| Interval diag. to SCTa | 0.007 | 0.96 (0.93–0.99) | 0.636 | 1.01 (0.98–1.03) | 0.306 | 0.98 (0.95–1.02) | 0.833 | 1.00 (0.97–1.02) | 0.108 | 0.98 (0.96–1.00) | 0.122 | 0.98 (0.96–1.00) |
| Disease status at SCT | ||||||||||||
| CR1 (ref) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
| CR2 versus CR1 | 4.10−5 | 1.50 (1.24–1.82) | 0.713 | 1.04 (0.85–1.28) | 0.728 | 1.04 (0.82–1.32) | 0.558 | 1.06 (0.88–1.28) | 0.002 | 1.25 (1.09–1.44) | 0.016 | 1.20 (1.03–1.39) |
| Act.dis. versus CR1 | <10−5 | 2.06 (1.76–2.42) | 0.001 | 1.35 (1.14–1.60) | 0.004 | 1.34 (1.1–1.63) | 0.019 | 1.22 (1.03–1.45) | <10−5 | 1.69 (1.51–1.90) | <10−5 | 1.63 (1.44–1.84) |
| Secondary AML | 0.699 | 0.97 (0.83–1.13) | 0.0004 | 1.32 (1.13–1.54) | 0.418 | 1.08 (0.90–1.30) | 0.196 | 1.11 (0.95–1.29) | 0.029 | 1.13 (1.01–1.26) | 0.021 | 1.14 (1.02–1.28) |
| Karnofsky ≥80 % | 0.149 | 0.83 (0.64–1.07) | <10−5 | 0.55 (0.43–0.70) | 0.838 | 0.97 (0.70–1.33) | 0.318 | 0.86 (0.64–1.16) | 10−5 | 0.68 (0.57–0.81) | <10−5 | 0.63 (0.58–0.76) |
| TBI | 0.005 | 1.26 (1.07–1.48) | 0.767 | 1.03 (0.85–1.24) | 0.088 | 0.83 (0.67–1.03) | 0.610 | 1.04 (0.88–1.24) | 0.019 | 1.16 (1.02–1.30) | 0.022 | 1.16 (1.02–1.32) |
| In vivo T cell depletion | 0.483 | 1.07 (0.89–1.27) | 0.253 | 0.90 (0.74–1.08) | <10−5 | 0.61 (0.49–0.75) | 0.0001 | 0.72 (0.61–0.85) | 0.790 | 0.98 (0.86–1.12) | 0.72 | 0.98 (0.85–1.12) |
| Female D to male R | 0.112 | 0.84 (0.68–1.04) | 0.172 | 1.15 (0.94–1.42) | 0.063 | 1.26 (0.99–1.61) | 0.078 | 1.19 (0.98–1.45) | 0.846 | 0.99 (0.85–1.14) | 0.896 | 1.01 (0.87–1.18) |
| High CMV risk (R+/D−) | 0.665 | 1.04 (0.87–1.24) | 0.002 | 1.35 (1.11–1.65) | 0.028 | 1.28 (1.03–1.60) | 0.814 | 0.98 (0.82–1.17) | 0.019 | 1.17 (1.03–1.33) | 0.001 | 1.25 (1.09–1.43) |
Act.dis. active disease, CR complete remission, D donor, D− donor, CMV serology, GVHD graft-versus-host-disease, LFS leukemia-free survival, NRM non relapse mortality, OS overall survival, PB Peripheral blood, Ref reference, R recipient, R+ positive recipient, CMV serology, SCT allogeneic stem cell transplantation, TBI total body irradiation
aAnalyzed per 6-month interval